Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or recurrent endometrial cancer.
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC)|
|Study Start Date:||June 2001|
|Primary Completion Date:||October 2002 (Final data collection date for primary outcome measure)|
- Determine the therapeutic activity of paclitaxel in patients with refractory or recurrent endometrial papillary carcinoma.
- Determine the objective response and duration of response in patients treated with this regimen.
- Determine the acute side effects of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 12 weeks.
PROJECTED ACCRUAL: Approximately 16-29 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00022620
|Allgemeines Krankenhaus der Stadt Wien|
|Vienna, Austria, A-1090|
|Universitair Ziekenhuis Antwerpen|
|Edegem, Belgium, B-2650|
|Leuven, Belgium, B-3000|
|Ospedale Mauriziano Umberto I|
|Torino, Italy, 10128|
|Voghera (PV), Italy, 27058|
|Hospitais da Universidade de Coimbra (HUC)|
|Coimbra, Portugal, 3049|
|Hospital Universitasrio San Carlos|
|Madrid, Spain, 28040|
|Queen Elizabeth Hospital|
|Gateshead, England, United Kingdom, NE9 6SX|
|Study Chair:||Gerald Gitsch, MD||Allgemeines Krankenhaus - Universitatskliniken|